Exeliom Biosciences
Latest round
- Series A
Last raised
- Apr 2025
Total raised
- $14M
Investors
- 9
About Exeliom Biosciences
Exeliom Biosciences, founded in 2016, is a biotechnology company based in Paris, France, specializing in immunomodulation. The company was co-founded by Benjamin Hadida and Harry Sokol. Exeliom specializes in innovative immunomodulation solutions, focusing on leveraging the NOD2 pathway to develop therapies addressing various disease areas. Their flagship product, EXL01, uses microbiome-based approaches to modulate immune responses, particularly enhancing macrophage polarization.Exeliom's revenue model is structured around strategic partnerships and collaborations with healthcare institutions and pharmaceutical companies, facilitating the distribution of their products. Transactions typically occur through B2B arrangements, with clients engaging in long-term agreements for the supply of EXL01 and related services. The company positions its offerings as premium solutions within the immunotherapy market, reflecting the advanced nature of their technology and its value to end-users.
Who invested in Exeliom Biosciences
9 investors across 4 rounds
See all investors in Exeliom Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Exeliom Biosciences
Who invested in Exeliom Biosciences?
Exeliom Biosciences has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Exeliom Biosciences raised?
Exeliom Biosciences has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Exeliom Biosciences last raise money?
Exeliom Biosciences's most recent round on record is a Series A, in Apr 2025.
What does Exeliom Biosciences do?
Exeliom Biosciences, founded in 2016, is a biotechnology company based in Paris, France, specializing in immunomodulation.
Where is Exeliom Biosciences headquartered?
Exeliom Biosciences is headquartered in Paris, France.
Which VCs invest in companies like Exeliom Biosciences?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Exeliom Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Exeliom Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.